Creative Planning Buys 4,120 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Creative Planning grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 35.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,640 shares of the biopharmaceutical company’s stock after buying an additional 4,120 shares during the period. Creative Planning’s holdings in Agios Pharmaceuticals were worth $695,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Farallon Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after purchasing an additional 63,900 shares in the last quarter. Vanguard Group Inc. boosted its stake in Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after buying an additional 44,583 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares in the last quarter. Marshall Wace LLP boosted its stake in Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after buying an additional 855,739 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Agios Pharmaceuticals by 5.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,108,613 shares of the biopharmaceutical company’s stock worth $32,416,000 after buying an additional 62,153 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $44.87 on Monday. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of 3.95, a PEG ratio of 0.45 and a beta of 0.75. The stock’s 50-day simple moving average is $44.62 and its two-hundred day simple moving average is $42.23. Agios Pharmaceuticals, Inc. has a 52-week low of $20.40 and a 52-week high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 3.81% and a net margin of 2,051.38%. The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the business earned ($1.51) EPS. As a group, equities analysts forecast that Agios Pharmaceuticals, Inc. will post 7.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AGIO has been the subject of several research reports. Scotiabank upped their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research note on Friday. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $52.33.

Insider Activity at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.